Plozalizumab Plevistinag

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 12:40:06 GMT 2025` Edited by `admin` on `Wed Apr 02 12:40:06 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG1\|KAPPA
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	P5H59ZL4XA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

H-gamma1 heavy chain humanized (1-447) [VH (Homo sapiens IGHV3-73*01 (86.9%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [8.10.8] (26-33.51-60.99-106)) (1-117) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 6-G1v3-1 A1.2, A1 (CH1 K120 (214) (118-215), hi

Preferred Name

English

Plozalizumab Plevistinag

Common Name

English

Immunoglobulin G1, anti-(human CC chemokine receptor CCR2) (human-Mus musculus monoclonal 1D9 ?1-chain), disulfide with human-Mus musculus monoclonal 1D9 ?-chain, dimer, thioether with [P(R)]-2?-deoxy-2?-fluoro-5?-O-[(R)-hydroxymercaptophosphinyl]-N-[2-[

Common Name

English

immunoglobulin G1-kappa, anti-[Homo sapiens CCR2 (chemokine (C-C motif) receptor 2, C-C chemokine receptor 2, CC-CKR-2, CKR-2, monocyte chemoattractant protein 1 receptor, MCP-1-R, CD192)], humanized monoclonal antibody, conjugated, on an average of 3.8-

Common Name

English

plozalizumab plevistinag [INN]

Common Name

English

Code System Code Type Description

CAS

2983832-01-3

Created by admin on Wed Apr 02 12:40:06 GMT 2025 , Edited by admin on Wed Apr 02 12:40:06 GMT 2025

PRIMARY

INN

13431

Created by admin on Wed Apr 02 12:40:06 GMT 2025 , Edited by admin on Wed Apr 02 12:40:06 GMT 2025

PRIMARY

FDA UNII

P5H59ZL4XA

Created by admin on Wed Apr 02 12:40:06 GMT 2025 , Edited by admin on Wed Apr 02 12:40:06 GMT 2025

PRIMARY

From	To
1_22	1_98
1_144	1_200
1_261	1_321
1_367	1_425
2_22	2_98
2_144	2_200
2_261	2_321
2_367	2_425
3_23	3_93
3_139	3_199
4_23	4_93
4_139	4_199
1_220	3_219
2_220	4_219
1_226	2_226
1_229	2_229

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_297
N	2_297

Related Record Type Details


					W4RT71M1YD

Dazostinag

CONJUGATE COMPONENT->CONJUGATE

Amount:


					4XG66BMN0D

PLOZALIZUMAB

PARENT -> CONJUGATE

Amount:


					92KA2XEZ4L

STIMULATOR OF INTERFERON GENES PROTEIN

TARGET -> ACTIVATOR

Interaction Type:

PRECLINICAL

Amount:

Related Record Type Details


					P5H59ZL4XA

Plozalizumab Plevistinag

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID REMOVAL	[1_447] [2_447]	C-TERMINUS	K		LYSINE	K3Z4F929H6
AMINO_ACID_SUBSTITUTION		RESIDUE_SPECIFIC	C	Amount:	UNSPECIFIED SUBSTANCE	80ad36bb (not in database)

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL